Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms.
The main questions it will answer are:
* Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis?
* Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study.
Participants will:
* Take drug ENV-294 once every day for 28 days
* Visit the clinic weekly for 4 weeks for checkups and tests
* Keep a diary of their symptoms and when they took their study drug ENV-294